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Abstract
BACKGROUND: Multiple sclerosis (MS) is an autoimmune-related neurological disorder as a result of chronic 
inflammation and demyelination which affect the central nervous system. The number of MS cases in Indonesia is 
about 1–5/100.000 people. This disease causes disability and requires immense treatment costs. One of the MS 
subtypes is primary progressive which is marked by the decline of neurological functions since the disease onset, 
without any period of relapse attacks. 
CASE REPORT: A 59-year-old female came with complaints on spinning dizziness, accompanied by vomiting and 
waddling for the past month before hospital administration. Based on physical examination, we found multiple cranial 
nerve palsies on the cranial nerve III, IV, V, VI, and VII on the left side. Initially, it suspected as an intracranial lesion 
in the cerebellopontine angle. However, brain computed tomography scan showed a normal result. Brain magnetic 
resonance imaging (MRI) was conducted and we found multiple lesions on the supratentorial and infratentorial 
region. The second patient was a 24-year-old female complained about waddling gait for the past year, which grew 
heavier. Based on physical examination, we found a cerebellar sign on the left side, cerebellar ataxia, paraparesis 
of lower extremity, and paresthesia. Brain MRI with contrast displayed white matter periventricular and infratentorial 
lesion. 
CONCLUSION: In both cases, radiological imaging examination, which was MRI with contrast, was beneficial in the 
establishment of patient’s diagnosis, which made therapeutic management suitable as needed.
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Introduction
Multiple sclerosis (MS) is a neurological 
disorder caused by chronic autoimmune demyelination 
related to the central nervous system (CNS) [1], 
[2]. Pathologies of demyelination disease are (1) 
destruction of the myelin sheath on nerve fibers, which 
the other nervous tissue elements such as axons, 
neuron cells, and their supporting structures remain 
intact, which is proven by the absence of Wallerian 
degeneration or other secondary degeneration; (2) 
infiltration from inflammatory cells to the perivascular 
region; and distribution from lesion to the white matter, 
either separate multiple small lesion focus or large 
lesions scattered from one or more lesions [3]. MS 
affects approximately 400,000 people in the United 
States or about 140/100,000 and in Europe is around 
108/100,000, which are mostly found on young 
individuals at the age of 20–50 [4], [5]. The prevalence 
of MS in Indonesia ranges at an estimate of 0–5/100,000 
[6]. The prevalence of MS in Indonesia ranges at an 
estimate of 5/100.000 and among 85% of MS patients 
suffer relapse and remission phase [6]. MS is thought to 
be the result of complex interactions between genetics 
and environment [2], [7]. Environment factors which 
play a role, among which are exposure to infections, 
exposure to sunlight, and Vitamin D. Pathogens are 
suspected to be involved on the MS pathogenesis are 
human herpesvirus type 6, Epstein-Barr virus, and 
Mycoplasma pneumonia [8]. Manifestations of MS can 
vary greatly. The quite typical symptoms consist of 
fatigue, depression, cognitive dysfunction, soreness, 
defecation and urination disturbance, visual impairment, 
vertigo, ataxia, tremors, extrapyramidal symptoms, 
sensory disturbance, and motor disorder [9].
Early MS diagnosis is primarily based on 
clinical features. McDonald criteria are the most 
common MS diagnosis criteria of The International 
Panel on Diagnosis of MS [10].
There are four clinical forms of MS, which are 
relapsing-remitting MS (RRMS), secondary progressive 
MS (SPMS), primary progressive MS (PPMS), and 
progressive relapsing MS (PRMS) [4].
Epidemiologically, airway infection can be 
related to MS relapse. Therefore, pathogen infection is 
believed to trigger autoimmune response toward CNS 
myelin on individuals who are genetically vulnerable 
through molecular mimicry of infection agents with 
myelin in the CNS, which leads to protein self-destruction 
as well as inflammation and demyelination disease [8].
Magnetic resonance imaging (MRI) is crucial to 
diagnose and manage MS. MS lesions are often found 
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on the periventricular, juxtacortical, infratentorial region 
of the brain, and spinal cord [1], [5].
Therapies for MS are classified into two types, 
which are immunomodulation therapy for the underlying 
immune process and therapy to reduce disease 
symptoms. In addition, non-pharmacological therapy in 
the form of physiotherapy and occupational therapy are 
also given [5], [9].
Case Report
The first case was the 59-year-old male who 
came to the emergency department with complaints 
on spinning dizziness and waddling gait for the last 
six weeks which became heavier accompanied by 
vomiting. Two months before hospital administration, the 
patient complained that he had difficulty in swallowing, 
thickening of the left side of his face, and closing of 
the left eyelid. The patient had a cardiac arrest when 
he was at the Emergency Department of Saiful Anwar 
Hospital, Malang, Indonesia. There was no history of 
similar complaints before and no similar complaint was 
experienced by the family.
Based on physical examination, the patient 
was intubated with GCS E4 VX M6, blood pressure 
at 100/70 mmHg, heart rate at 110 beats/min, and 
respiratory rate at 20 times/min. There were also 
multiple cranial nerves III, IV, V, VI, and VII palsies 
of the left side LMN type. Based on the EMG result, 
moderate axonal demyelinating motor and sensory 
polyneuropathy and bilateral phrenic nerve palsy were 
found. Blood gas analysis presented respiratory failure.
Brain computed tomography scan showed 
a normal result. Brain MRI result with contrast 
displayed (1) hyperintense lesion on left globus 
pallidus, mesencephalon, pons, and medulla oblongata 
suspected as MS with differential diagnosis vasculitis 
or metabolic disease, (2) chronic punctate hemorrhage 
with differential diagnosis cavernous malformation on 
the left temporal lobe, and (3) senile brain atrophy with 
Grade I Fazekas scale (Figure 1).
The patient was diagnosed as a suspect for 
PPMS. Throughout treatment, the patient received pulse 
methylprednisolone 4 × 250 mg for 5 days which was then 
Figure 1: Brain MRI with contrast
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continued with prednisone oral at 1 mg/kg bodyweight that 
was reduced gradually. The patient experienced respiratory 
failure and was intubated and placed on a ventilator during 
treatment in ICU. Provisions of corticosteroid according to 
therapy guideline did not give meaningful recovery on the 
patient, so plasmapheresis was added into the therapy. 
Throughout the treatments in ICU using ventilator, the 
patient had suffered from sepsis due to pneumonia related 
to ventilator use, with the result of bacterial culture was 
sensitive to the antibiotic tigecycline.
The second case was a 24-year-old female, 
complained cerebellar ataxic gait for the past year, 
accompanied with a double vision which grew 
increasingly heavy, lower back pain which spread to 
both of her legs, thickness from the hip to the sole, 
and weakness on both legs. These complaints never 
got better. She had an epileptic seizure 1 month before 
admission.
On physical examination showed that the 
patient’s GCS E4 V5 M6 with blood pressure at 110/70 
mmHg, heart rate at 82 beats/min, and respiratory rate 
at 18 times/min. It was found that there was a left cranial 
nerve VII palsy LMN type. We found positive cerebellar 
signs, dysmetria on the left side, balance disorder 
indicated by a positive Romberg test. There was also 
paraparesis on the lower extremity with MMT Scale 4. 
Physiological reflex increased by +3 on bilateral BPR, 
TPR, KPR, and APR (Figure 2).
Figure 2: Brain MRI with contrast
Brain MRI result with contrast showed (1) 
multifocal white matter lesion on the right lateral 
ventricle, right and left frontotemporal lobe, cerebellum, 
mesencephalon, and pons due to MS and (2) left 
thalamus chronic infarction. EEG result showed mild 
diffuse encephalopathy. We performed a perspiration 
test; the result indicated autonomic dysfunction at the 
T6 vertebrae level. The patient was planned to undergo 
a cervicothoracic MRI with contrast.
Our patient was diagnosed as suspect PPMS. 
Throughout treatment, the patient received pulse 
methylprednisolone 4 × 250 mg for 5 days. Previously, 
the patient had routinely consumed antiepileptic drug 
phenytoin for 2 × 100 mg and was continued during 
treatment at the Saiful Anwar Hospital.
Discussion
MS is thought to be the result of complex 
interactions between genetics and environment. Genomic 
studies showed that immune system plays an important 
role as the central influence on the pathogenesis of 
MS through MHC class II which is mapped in HLA-
DRB5*0101, HLA-DRB1*1501, HLA-DQA1*0102, and 
HLA-DQB1*0602 [3]. A study conducted on identical twins 
presented concordance ratio was 30%. Fathers who 
suffer from MS have the risk to inherit the MS to their sons 
by 1% and their daughters by 2%. Meanwhile, the siblings 
of an individual with MS have the risk of contracting MS by 
3-4%, as do non-identical siblings [2], [8].
The diagnosis of MS is established clinically 
and there is no definite examination for MS. Diagnosis 
establishment requires neurological assessment and 
clinical observation in a certain period of time [2], [5], [10].
In general, MS patients come with remission 
and exacerbation symptom and sign. Diagnosis for MS 
must be considered on patients who come with their first 
episode of neurological symptoms or signs which support 
a demyelination process and have no other possible 
causes. The first episode of this clinical manifestation is 
called Clinically Isolated Syndrome (CIS) [4].
Clinical manifestations which should be suspected 
as MS symptoms comprise of the decrease of visual 
acuity on either both of eyes which may be accompanied 
with soreness during eyeball movement, double vision, 
sensory disturbance and/or weakness, balance problems, 
and positive Lhermitte’s sign [3] (Table 1).
Table 1: McDonald criteria 2010 [10]
Clinical presentation Additional data needed for diagnosis
≥2 clinical attacks and objective 
evidence of ≥2 lesions
None
≥2 clinical attacks and objective 
evidence of 1 lesion
DIS: An additional attack implicating a different CNS 
site OR by MRIa
1 clinical attack and objective 
evidence of ≥2 lesions
DIT: An additional clinical attack
OR by MRIb
OR
CSF-specific oligoclonal bands
1 clinical attack and objective 
evidence of 1 lesion
DIS: An additional clinical attack implicating a different 
CNS site
OR by MRIa
OR
DIT: An additional clinical attack
OR by MRIb
OR
CSF-specific oligoclonal bands
Adapted from Thompson AJ, Banwell BL, Barkhof, et al. Diagnosis of multiple sclerosis: 2017 revisions of 
the McDonald criteria. Lancet Neurol. 2018; 17:162-73. CNS: Central nervous system, CSF: Cerebrospinal 
fluid, DIS: Disseminated in space, DIT: Disseminated in time, MRI: Magnetic resonance imaging. aDIS by 
MRI: New lesions on follow-up imaging or both gadolinium-enhancing and non-enhancing lesions on single 
MRI, bDIS by MRI: ≥1 symptomatic or asymptomatic lesion in ≥2 areas including cortical/juxtacortical, 
periventricular, infratentorial, or spinal.
Natural immune response plays a positive role 
in the initiation and progressivity of MS disease. The link 
between pathogen-associated molecule and toll-like 
receptors will activate the dendritic cell (DC). Immature 
DC becomes semi-mature and induces regulatory T 
cells to produce cytokine IL-10 and TGF-β. After DC 
has matured, DC induces CD4+ T cells to differentiate 
into Th1, Th2, and Th17. The differentiation of T cell into 
Th1 will lead to inflammation [3].
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Adaptive immune response triggered by APC 
which presents specific antigen to T lymphocytes, thus 
activating CD4+ and CD8+ T lymphocyte. Cells that may 
be involved as APC are B lymphocyte, DC, microglia, 
and macrophage. TH1 secretes pro-inflammatory 
cytokine interferon-gamma, while Th2 secretes anti-
inflammatory cytokine IL-4 and IL-13. Th17 secretes 
IL-17, IL-21, IL-22, and IL-26. Th17 also triggers the 
inflammation process on MS. During MS, Th1 and TH17 
cells migrate to the CNS and cause demyelination and 
axonal lesions. CD8+ cells also kill glia cells which cause 
axons to be exposed. CD8+ T cells attach to axon and 
increase vascular permeability and trigger the death of 
oligodendrocytes [1], [2], [8].
B cells play a role in the pathogenesis of 
MS by transforming into plasma cells and producing 
antibodies. The presence of a polyclonal antibody 
in the cerebrospinal fluid of MS patients is known as 
oligoclonal bands [9] (Figure 3).
Figure 3: Immunology process on the central nervous system
There are four clinical types of MS, which 
are RRMS, SPMS, PPMS, and PRMS [2] RRMS is 
the most often occurring type, accounting for 85%. 
RRMS is more frequently found on women than on 
men with a ratio of 2:1 and average onset at the age 
of 29. RRMS is marked by acute attacks (relapse) 
which are followed by full recovery (remission) and 
partial recovery that contrasts PPMS. The prevalence 
of PPMS is 10–15% of MS. On average, PPMS is 
diagnosed at the age of 40 and its prevalence for both 
men and women is the same. PPMS is marked by the 
continuation and irreversibility of disease progressivity 
[2] [11] (Figure 4).
Figure 4: Multiple sclerosis subtypes [11]
MS can resemble other diseases, which 
means that before coming to the diagnosis of MS, other 
differential diagnoses, for instance, CNS infection, 
cerebrovascular disease, and other autoimmune 
diseases, such as NMO, SLE, neoplasm, and metabolic 
caused must be removed first [5].
Radiological imaging, especially MRI, is crucial 
for diagnosing and managing MS [5]. MRI can tell apart 
lipids from water. Myelin primarily consists of lipid, 
meaning that regions that experience demyelination 
contain more water. This in turn causes the demyelinated 
region to show darker colors on T1 and bright colors on 
T2. On T1, water is colored darker and lipid is colored 
brighter, and conversely, on T2 [5], [7].
MRI imaging of T1 is more sensitive 
when contrast is used, for instance, gadolinium 
diethylenetriaminepentaacetic acid. Gadolinium-
enhanced can indicate the presence of disturbance 
at the blood-brain barrier on the acute lesion and the 
presence of a new lesion in CNS (particularly brain). 
Figure 5: Specific location of MS [8]
Therefore, T1 MRI with contrast can 
distinguish acute and chronic lesions. MS lesions 
can often be found in the periventricular, juxtacortical, 
and infratentorial region of the brain and spinal cord. 
Dawson’s finger is a specific lesion in MS [10]. What is 
meant by Dawson’s finger is an ovoid lesion around the 
ventricle which exists due to demyelination along the 
small veins in cerebri [1], [8] (Figures 5 and 6).
Figure 6: Image of Dawson’s finger [8]
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Other supporting examination which can assist 
in establishing the diagnosis for MS is evoked potential 
and cerebrospinal fluid examination, though the two are 
not specific for MS. For EVP, if linear with lesion then 
it can be objective clinical evidence. For cerebrospinal 
fluid examination, IgG and oligoclonal band have high 
sensitivity, but they are not specific to MS [5].
Disease modification therapy is mainly 
conducted for controlling the underlying processes of 
disease instead of curing or even reversing the damages 
due to earlier attacks. Provided medications also aim 
to lessen disease symptoms. Therapies used for the 
acute phase are methyl prednisolone, among others. 
In the event that contraindication occurs for steroid 
administration, plasma exchange is given for severe 
attacks or when the steroid is proven ineffective [3].
The purpose of treatments on PPMS patients 
is to stabilize the disease, to provide supportive therapy, 
and to improve living quality. Until today, there has yet a 
recommended medication for PPMS [4].
Prognosis of MS patients presents 30% of 
which experience disabilities within 20–35 years. 
Only 5–10% of patients have a mild case of MS. 
Most individuals who have MS die due to secondary 
complications, such as pneumonia or kidney diseases, 
while only a small fraction die due to suicide or causes 
not relevant to MS. Relapsing and remitting can happen 
after 15 years [2].
For the first case, the patient experienced 
vertigo, spinning sensation, and multiple cranial nerve 
palsy which was not typical to MS, initially suspected as 
a form of intracranial lesion heading toward a tumor in 
the cerebellopontine angle.
For the second patient, the appearing 
symptoms were cerebellar ataxia, which is accompanied 
by weakness in her lower extremities, paresthesia at 
the T6 myelum level. On both patients, we found neither 
body heat nor infection signs which constantly for more 
than 24 h. Supporting examination was done through 
brain MRI with contrast which led to the diagnosis 
of MS.
Clinically, both patients fulfilled the CIS 
criteria, which are monofocal or multifocal disorder and 
generally related to the optic nerve, cerebellum, spinal 
cord, and cerebral hemisphere, all of which were able 
to be used for McDonalds criteria revised in 2010 as a 
diagnosis for MS [10].
Based on anamnesis and physical and 
supporting examinations for these patients, diagnosis 
of MS favored toward primary progressive subtype.
The patients were given high doses 
corticosteroid therapy that is methylprednisolone 
for 5 days. Both first and second patients did not 
show good responses and complaints still remained. 
For the following management, patients were given 
immunosuppressant drugs such as azathioprine and 
methotrexate. The first patient suffered from secondary 
complications and required treatments in ICU with a 
ventilator. Meanwhile, the second patient was able to 
carry out therapy through the polyclinics, despite still 
having persistent complaints.
Conclusion
MS is a neurological disorder as a result of 
chronic autoimmune demyelination which is related 
to the CNS. The diagnosis for MS used McDonalds 
criteria revised in 2010. Therapies consisted of 
pharmacological, which comprised causative and 
symptomatic therapy, as well as non-pharmacological 
such as physiotherapy. In both cases, MRI, as a 
radiological imaging examination with contrast, was 
found to be very helpful in establishing a patient’s 
diagnosis; therefore, therapeutic management can be 
given according to their conditions.
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